论文部分内容阅读
目的研究抑癌基因PTEN和胰岛素样生长因子1受体(IGF1R)与子宫内膜癌临床及病理特征的关系。方法应用免疫组织化学方法(SP法)检测45例子宫内膜癌组织中PTEN基因和胰岛素样生长因子1受体的表达。结果45例子宫内膜癌组织中,PTEN阳性表达率为28.89%;Ⅰ期患者和Ⅱ～Ⅲ期患者阳性表达率分别为44.00%和10.00%(P<0.05);在高、中、低分化子宫内膜癌中的阳性表达率分别为60.00%、15.00%和10.00%(P<0.05);无、有淋巴结转移者的阳性表达率分别为38.71%和7.14%(P<0.05);IGF1R阳性表达率为86.67%。结论PTEN基因抑制子宫内膜癌的生长、浸润及淋巴结转移;IGF1R在子宫内膜癌的发生中发挥着重要作用。
Objective To study the relationship between tumor suppressor gene PTEN, insulin-like growth factor 1 receptor (IGF1R) and clinical and pathological features of endometrial carcinoma. Methods Immunohistochemistry (SP method) was used to detect the expression of PTEN gene and insulin-like growth factor 1 receptor in 45 cases of endometrial carcinoma. Results The positive expression rates of PTEN in 45 cases of endometrial carcinoma were 28.89%. The positive rates of PTEN in stage Ⅰ and stage Ⅱ ~ Ⅲ were 44.00% and 10.00%, respectively (P <0.05) The positive expression rate of endometrial carcinoma was 60.00%, 15.00% and 10.00%, respectively (P <0.05). The positive rate of non-lymph node metastasis was 38.71% and 7.14% respectively (P <0.05) The expression rate was 86.67%. Conclusions PTEN gene inhibits the growth, invasion and lymph node metastasis of endometrial carcinoma. IGF1R plays an important role in the pathogenesis of endometrial carcinoma.